A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses

Abstract Vaccination is considered to be one of the most effective tools to decrease morbidity as well as mortality caused by influenza viruses.

[1]  M. Garcés-Sánchez,et al.  Pediatric Safety Evaluation of An AS-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3–9 Years: A Phase II Study , 2008 .

[2]  P. Gillard.  Immunogenicity Evaluation of an AS03-Adjuvanted H5N1 Prepandemic Candidate Vaccine in Children Aged 3-9 Years , 2008 .

[3]  T. Vesikari.  Efficacy of an Inactivated Split-Virus Influenza Vaccine , 2008 .

[4]  J. Richardus,et al.  Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. , 2008, Vaccine.

[5]  C. Furlanello,et al.  Mitigation Measures for Pandemic Influenza in Italy: An Individual Based Model Considering Different Scenarios , 2008, PloS one.

[6]  G. Leroux-Roels,et al.  Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine , 2008, PloS one.

[7]  F. Hayden,et al.  Update on avian influenza A (H5N1) virus infection in humans. , 2008, The New England journal of medicine.

[8]  A. Osterhaus,et al.  Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine , 2008, PloS one.

[9]  R. Schmidt-Ott,et al.  Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. , 2007, Vaccine.

[10]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[11]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[12]  A. Osterhaus,et al.  Pre- or post-pandemic influenza vaccine? , 2007, Vaccine.

[13]  D. Skowronski,et al.  Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. , 2007, Vaccine.

[14]  J. Wood,et al.  Reference viruses for seasonal and pandemic influenza vaccine preparation , 2006, Influenza and other respiratory viruses.

[15]  R. Webster,et al.  H5N1 influenza--continuing evolution and spread. , 2006, The New England journal of medicine.

[16]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[17]  C. Cooper,et al.  Fluarix™, inactivated split-virus influenza vaccine , 2006, Expert opinion on biological therapy.

[18]  W. Keitel,et al.  Rapid Licensure of a New, Inactivated Influenza Vaccine in the United States , 2005, Human vaccines.

[19]  R. Cox,et al.  Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice , 2005, Scandinavian journal of immunology.

[20]  V. Ferro.  Improved design of the annual influenza vaccine using epitope analysis , 2005 .

[21]  J. Langley,et al.  Prevention of influenza in the general population , 2004, Canadian Medical Association Journal.

[22]  M. Deem,et al.  Epitope analysis for influenza vaccine design. , 2004, Vaccine.

[23]  E. Neumeier,et al.  Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. , 2004, Virus research.

[24]  A. Hay,et al.  Recent changes among human influenza viruses. , 2004, Virus research.

[25]  C. Bridges,et al.  Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2004, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[26]  K. Nichol,et al.  The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. , 2003, Vaccine.

[27]  C. V. Hoecke,et al.  Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix™ , 2002 .

[28]  E. Neumeier,et al.  Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines , 2002, Medical Microbiology and Immunology.

[29]  J. Taubenberger,et al.  Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Künzel,et al.  Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. , 1996, Vaccine.

[31]  G. Dinant,et al.  The Efficacy of Influenza Vaccination in Elderly Individuals: A Randomized Double-blind Placebo-Controlled Trial , 1994 .

[32]  K. Nichol,et al.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.

[33]  E. D'hondt,et al.  Immune response to influenza vaccination , 1994, The Lancet.

[34]  A. Kendal,et al.  Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. , 1992, The Journal of general virology.

[35]  Y. Kanegae,et al.  Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season , 1990, Journal of virology.

[36]  A. Kendal,et al.  Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. , 1990, Virology.

[37]  R. J. Webby,et al.  Influenza vaccines. , 2009, Vaccine.

[38]  M. Elizabeth Halloran,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[39]  V. Prikazsky,et al.  Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. , 1996, Gerontology.